SAN MATEO, CA, JUNE 01, 2023 - BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning (AI/ML) - guided antibody discovery and development platform, today announced the appointment of John Corbin, PhD, as Chief Development Officer. Dr. Corbin is a drug development leader with extensive experience advancing new therapies through preclinical and early clinical development. Most recently John was Chief Technology Officer at Tizona Therapeutics developing antibodies to treat cancer and autoimmune diseases.
“John brings a remarkable breadth of experience in antibody design and development in multiple disease areas.” said Mark DePristo, Ph.D., Chief Executive Officer and Co-founder of BigHat Biosciences. “We couldn't be more excited to work with John in this critical role to expand and advance our pipeline of therapeutic programs to have an impact for patients.”
Dr. Corbin’s career spans almost two decades in the biopharmaceutical industry. He joins BigHat Biosciences from Tizona Therapeutics (Gilead Sciences, Inc. minority owner) where he served as Chief Technology Officer, leading the antibody discovery and engineering, protein sciences and CMC of therapeutic antibodies for all Tizona pipeline programs. Prior to joining Tizona, Dr. Corbin oversaw antibody discovery and engineering at Gilead Sciences (GILD) for multiple therapeutic areas including oncology and HIV. In addition, Dr. Corbin was a project team leader for therapeutic antibody programs ranging from early stage through Investigational New Drug-enabling development. Previously, he was at XOMA serving in several roles with increasing responsibility. Notably, he also led XOMA’s insulin receptor antagonist program (XOMA 358) from inception through lead selection, which was acquired by Rezolute Bio (RZLT) and completed Phase 2 clinical trials. Dr. Corbin received his Ph.D. in Biology from University of California at Santa Cruz and completed his postdoctoral research at the University of Colorado at Boulder. Dr. Corbin has published in numerous peer-reviewed journals and is an inventor on many antibody patents, with proprietary molecules in Phase 1b and 2 clinical trials, while another has concluded Phase 1b.
“I am thrilled to join BigHat at this exciting time when we are employing our cutting edge antibody discovery and engineering platform to build our therapeutic pipeline” said Dr. Corbin. “I look forward to working with the team to bring important new medicines to patients.”